On March 31, 2023, Piper Sandler initiated coverage of Immunovant with a Overweight recommendation. Analyst Price Forecast Suggests 56.52% Upside…
On March 30, 2023, Stifel initiated coverage of Immunovant with a Buy recommendation. Analyst Price Forecast Suggests 56.92% Upside As…